An Open Label Phase I Study of Gemcitabine/Oxaliplatin (GEMOX) and Vandetanib (ZACTIMA; ZD6474) Combination in Patients With Advanced Solid Malignancy (IRUSZACT0070) (UPCI 07-025).

Trial Profile

An Open Label Phase I Study of Gemcitabine/Oxaliplatin (GEMOX) and Vandetanib (ZACTIMA; ZD6474) Combination in Patients With Advanced Solid Malignancy (IRUSZACT0070) (UPCI 07-025).

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jan 2014

At a glance

  • Drugs Vandetanib (Primary) ; Gemcitabine; Oxaliplatin
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Jan 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 17 Jan 2013 Planned end date changed from 1 Oct 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov.
    • 28 Apr 2011 Planned end date changed from 1 Oct 2010 to 1 Oct 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top